Short answer
LEMAITRE VASCULAR INC (LMAT) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $61M (up 11.4% year over year) with net income of $17M.
Q3 2025 key financials · XBRL
- Revenue
- $61M
- +11.4% YoY · −5.0% QoQ
- Net income
- $17M
- +55.8% YoY · +26.0% QoQ
- Operating margin
- 33.3%
- Gross margin
- 75.3%
- EPS (diluted)
- $0.76
- +55.1% YoY · +26.7% QoQ
Source: XBRL data from the LEMAITRE VASCULAR INC (LMAT) Q3 2025 10-Q on SEC EDGAR. USD.
LEMAITRE VASCULAR INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New product recall risk triggered by April 2025 inadequate seal issue on TufTex, Pruitt Occlusion, and Pruitt Irrigation catheters packaging
- Updated regulatory risk: August 2025 FDA warning letter to Artegraft facility, no material financial impact or sales disruption reported
- Regulatory risk of approvals withdrawn or suspended in US and EU, potentially triggering cascading regulatory actions across jurisdictions
- Market risk from global economic slowdown and tariffs possibly reducing customer spending and increasing import costs outside US
- Financial risk from costs and capital dedication due to recalls, liability claims, and regulatory corrective actions impacting results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LEMAITRE VASCULAR INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.